Integra LifeSciences Reports Third Quarter 2026 Financial Results

Integra LifeSciences reported Q3 2026 revenues of $411.2 million (up 2.5% organically) with adjusted EPS of $0.59, impacted by ~$7 million in flood damage at its Cincinnati facility. The company completed a $2.1 billion debt refinancing to extend maturities and enhance financial flexibility. Full-year 2026 guidance maintained at $1.634-1.654 billion in revenues and $2.30-2.40 adjusted EPS, reflecting recovery expectations and softer Tissue Reconstruction performance.